GlassScriptPhysician profile
Douglas A Neeld
NPI 1780669374
$76,544.05
in general payments reported to CMS, 2019-2025
30 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $6,229 · 2021: $24K · 2022: $14K · 2023: $19K · 2024: $11K · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $4,363 · Travel and Lodging: $276 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Food and Beverage | $4,363.23 |
| Travel and Lodging | $276.47 |
| Education | $103.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68,944.49 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,769.95 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Csl Behring | $1,252.85 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Genzyme Corporation | $856.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $816.07 | 2020-2025 | Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $357.67 | 2019-2025 | Dupixent |
| Amgen INC. | $250.83 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $244.08 | 2021-2024 | Orladeyo |
| Pharming Healthcare, INC. | $225.59 | 2019-2024 | Ruconest |
| Genentech USA, INC. | $224.46 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $183.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.15 | 2019-2023 | Spiriva Respimat |
| Octapharma USA, INC. | $178.44 | 2019-2025 | Cutaquig |
| Kaleo, INC. | $151.69 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $143.65 | 2025 | Neffy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $113.46 | 2019 | |
| Grifols USA, LLC | $104.42 | 2020 | |
| Bio Products Laboratory USA, INC. | $74.74 | 2019 | |
| Optinose US, INC. | $64.99 | 2019-2020 | |
| Pfizer INC. | $63.22 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $62.10 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $59.91 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.67 | 2022 | |
| Hospira, INC. | $33.74 | 2024 | |
| Alk-Abello, INC | $31.94 | 2019-2025 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Merck Sharp & Dohme LLC | $27.31 | 2021-2023 | |
| Blueprint Medicines Corporation | $24.46 | 2023 | Ayvakit |
| Sunovion Pharmaceuticals INC. | $18.52 | 2019 | |
| Abbvie INC. | $15.26 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Neeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.